...
首页> 外文期刊>The Journal of dermatological treatment >Severe antiphospholipid antibody syndrome - response to plasmapheresis and rituximab
【24h】

Severe antiphospholipid antibody syndrome - response to plasmapheresis and rituximab

机译:严重的抗磷脂抗体综合征 - 对血浆丸剂和利妥昔单抗的反应

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Antiphospholipid antibody syndrome (APS) is a systemic autoimmune disease characterized by arterial and/or venous thrombosis, recurrent abortions and detection of antiphospholipid antibodies. In fulminant cases, involvement of multiple organs can lead to significant morbidity and even fatal outcomes, so that a rapid, interdisciplinary treatment is needed. Here, we describe the case of a 39-year-old woman with a severe hard-to-treat APS with arterial occlusion and progressive skin necrosis, who was successfully treated with a combination therapy with plasmapheresis and rituximab. The treatment led to complete remission of the skin lesions for over a year. Clinical response correlated with a long-lasting reduction of antiphospholipid antibodies and B-cell depletion. This case demonstrates the use of antiphospholipid antibodies for monitoring APS-activity and shows that this severe vascular disease requires rigorous therapeutic approaches.
机译:抗磷脂抗体综合征(APS)是一种系统性自身免疫疾病,其特征在于动脉和/或静脉血栓形成,复发性堕胎和抗磷脂抗体的检测。 在令人兴奋的病例中,多种器官的涉及可能导致显着的发病率甚至致命的结果,因此需要快速,跨学科的治疗。 在这里,我们描述了一个39岁女性的案例,具有严重的难以治疗的APS,具有动脉闭塞和渐进式皮肤坏死,他已成功地用血浆丸剂和利妥昔单抗进行组合治疗。 治疗导致每年完全缓解皮肤病变。 临床反应与抗磷脂抗体和B细胞耗竭的长持久减少相关。 本例证明了使用抗磷脂抗体用于监测APS活性,并表明这种严重的血管疾病需要严格的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号